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Poster Session I S225report the results of a single-center, prospective evaluation for IO
and its subsequent treatment in 147 allo HCT survivors. Adult
(.18 years) allo HCT recipients were eligible for this study if
(1) they had survived for $1 year post-HCT, (2) were in remis-
sion from their primary disease, (3) had no uncontrolled infection
or GVHD, (4) had no contraindication for MRI, (5) had ade-
quate blood counts and renal and hepatic function, and (6) had
significant IO. Patients were screened with serum ferritin, and
those with ferritin .1000 ng/mL underwent liver R2 MRI to es-
timate liver iron concentration (LIC, normal #1.8 mg/g). Signif-
icant IO was defined as LIC $5 mg/g. Based on physician and
patient preference, patients with significant IO were offered ob-
servation only, phlebotomy, or were enrolled on a pilot study
of deferasirox (if phlebotomy was not feasible [hemoglobin
\11 g/dL] or was refused). 23 patients had IO (LIC .1.8) and
16 had significant IO (LIC $5). Among patients with significant
IO, 69% had acute leukemia and 56% had received myeloabla-
tive conditioning. The median baseline LIC was 10.0 (range,
5.1-43). All patients were transfusion independent at enrollment.
Five patients received no treatment (median LIC 6.4), 8 under-
went phlebotomy (median LIC 13.1) and 3 received daily defer-
asirox 20 mg/kg/day for 6 months (median LIC 6.3). Two
patients had abnormal liver function tests and one patient each
had cirrhosis and unexplained heart failure; all four received
phlebotomy. Followup serum ferritin decreased spontaneously
in 4 patients on the observation arm (median ferritin, 1606 at
baseline to 1264 at followup); 1 also had followup MRI (LIC de-
creased from 6.4 to 2.3). Phlebotomy was well tolerated and no
patient needed ESA’s to facilitate phlebotomy. Deferasirox was
well tolerated and led to a decrease in LIC in all 3 patients
(baseline to 6 mo LIC: 6.3 to 2.8, 9.0 to 6.8, 19.9 to 8.8).
Mild adverse events were observed that did not require discontin-
uation of drug therapy. Phlebotomy is feasible in the majority of
allo HCT recipients who have survived for $1 year after HCT
and have significant IO. Iron levels may decrease with time with-
out any therapy in selected allo HCT survivors. Although the
numbers are small, deferasirox may be a safe and effective alter-
native for allo HCT survivors with IO who cannot undergo phle-
botomy.181
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Background:Large granular lymphocytes (LGLs) are amorpholog-
ically distinct but an immunophenotypically heterogeneous set of
lymphocytes of activated T- orNK cells that mediate non-MHC-re-
stricted cytotoxicity. LGL expansion following allogeneic hemato-
poietic stem cell transplantation (HSCT) has been reported
although its clinical relevance on transplant outcomes is not clear.
Moreover, precipitating factor evoking LGL expansion is unknown.
Methods: A total of 323 consecutive patients who received alloge-
neic HSCTs from HLA identical sibling donors between January
2000 andOctober 2007 at the PrincessMargaret Hospital, Toronto,
Canada, were included in the retrospective study. The patients’ char-
acteristics were: gender (male/female5 196/127); median age 49.5
yrs (range 17-71); stem cell source (PBSC/BM5 25172); condition-
ing (myeloablative/reduced intensity5 228/95). The definition of
LGL expansion is as follows: 1) increasing number of peripheral
blood lymphocyte counts$ 3.0109/L for at least 3 months, and
2) the predominance of LGLs in the peripheral blood smears.
Results: Out of 323 recipients, 64 cases (19.8%) showed LGL ex-
pansion after allogeneic hematopoietic stem cell transplantation
(HSCT). The median onset of LGL expansion was 306 days (95%C.I. 205-407 days). The 1- and 2-year(s) incidence of LGL expan-
sion was 14.46 2.2% and 22.06 2.8%.
Compared to the patients without LGL expansion, improved
transplant outcomes were observed in patients with LGL expan-
sion: better overall survival (2 years OS; 94.8% vs 60.3%,
p\0.001), lower non-relapse mortality (2 years NRM; 2.6% vs
23.4%, p\0.001) and lower relapse incidence (5.6% vs 29.5%,
p\0.001).
Three risk factors were identified for the development of LGL ex-
pansion such as CMV serostatus of recipient, CMV reactivation, and
occurrence of chronic GVHD. Higher incidence of LGL expansion
was noted 1) in recipient CMV IgG (+) group (CMV-R+) compared
to CMV-R- group regardless of CMV serostatus of donor (52/193
[27%] vs 11/128 [9%]; p\0.001); 2) in patients experiencing
CMV reactivation (43/140 [31%] vs 21/183 [11%]; p\0.001); 3)
in patients developing chronic GVHD (61/252 [24%] vs 2/55
[4%]; p5 0.02).
Conclusion: LGL expansion is not uncommon following alloge-
neic HSCT with HLA-identical sibling donors, and strongly as-
sociates with favorable transplant outcomes esp. in terms of non-
relapse mortality. Its association with chronic GVHD suggested
that expanded LGLs may mediate GVL effect after allogeneic
HSCT.182
PERIPHERAL AIRWAY FUNCTION DECLINES FOLLOWING ALLOGENEIC
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Bronchiolits Obliterans (BO) is the most frequent non-infec-
tious pulmonary complication post allogeneic stem cell transplant
(SCT) and is strongly correlated with cGVHD. BO remains
a major cause of late post SCT morbidity and mortality. Airflow
obstruction as detected by spirometry occurs late in BO, only
when widespread small airways disease is well established and
the process is more likely to be irreversible. The Multiple Breath
Nitrogen Washout (MBNW) test is a sensitive and reproducible
measure of peripheral airway function that is highly sensitive to
bronchiolitis in smokers with otherwise normal spirometry. Its
role in assessing peripheral airway dysfunction and early BO
post SCT has not been assessed. In a cross sectional study, 30
pts post SCT (mean age 47, 19-68 yrs) underwent standard spi-
rometric and lung volume testing together with measurements of
acinar (Sacin) and conductive (Scond) peripheral airway ventila-
tory heterogeneity and Lung Clearance Index (LCI) as assessed
by MBNW. Median time post SCT was 12 (3-73) mths, with
most pts receiving reduced intensity conditioning (17/30) for
acute leukemia (15/30). 50% had prior aGVHD, though no pts
had active aGVHD at the time of testing. 20/30 pts had
cGVHD, with 18 pts having active disease at the time of testing.
40% had moderate/severe cGVHD by NIH Consensus Criteria.
27% cohort had evidence of airway obstruction (FEV1/FVC
\70% predicted), while abnormal Sacin (.0.3L21) and Scond
(.0.04L21) affected 73% and 80% respectively. Sacin, Scond
and LCI were inversely correlated to FEV1% predicted while
Scond and LCI were correlated with RV/TLC% predicted. 1
pt with evidence of obstruction had normal Sacin, while 13 pts
with normal spirometry had abnormal Sacin. On univariate anal-
ysis, poorer FEV1/FVC%, Sacin, Scond and LCI measures were
strongly associated with days post transplant, but only Sacin
(p5 0.016) and Scond (p5 0.014) were significantly associated
with a diagnosis of cGVHD. Poorer Sacin was also correlated
with increasing severity of cGVHD (R25 0.48, p5 0.002). On
multivariate analysis only cGVHD (p5 0.01) remained an inde-
pendent predictor of abnormal Sacin. Peripheral airway function
appears to decline following SCT, and is strongly associated with
the development of cGVHD. Prospective studies are being
S226 Poster Session Iundertaken to assess whether the MBNW test can be used as an
early marker of BO in asymptomatic pts.183
LATE ONSET NON-INFECTOUS PULMONARY COMPLICATIONS (LONIPC)
IN ADULT ALLOGENEIC HEMATOPOEITIC CELL TRANSPLANT (HCT) RE-
CIPIENTS
Solh, M., Cao, Q., Majhail, N.S., Weisdorf, D. University of Minnesota,
Minneapolis, MN
LONIPC after allogeneic HCT can contribute to post-transplant
morbidity and mortality and decreased quality of life. We reviewed
data for LONIPC in 451 consecutive adult patients who received
an allogeneic HCT between 2002 and 2007 and survived for $80
days after HCT. Seventy four patients developed LONIPC at a me-
dian of 177 (range, 81-1017) days after HCT; 1-year cumulative in-
cidence of LONIPC was 13% (95% CI, 10%-16%). LONIPC
occurred among 21.3% of myeloablative and 12.6% of non-myeloa-
blative HCT recipients. Graft sources were 49% related donor, 45%
umbilical cord blood and 51% unrelated donor. Acute GVHD had
occurred in 49%. 53% of patients had a prior history of or concom-
itant chronic GVHD. Four groups of LONIPC were observed: dif-
fuse alveolar hemorrhage (DAH, n5 28), idiopathic pneumonia
syndrome (IPS, n5 19), bronchiolitis obliterans (BO, n5 22) and
other (n5 5). A greater proportion of patients with LONIPChad re-
ceived myeloablative conditioning compared to patients who did not
develop LONIPC (57% vs 41%, p5 0.01); the two groups were oth-
erwise comparable. Overall survival at 1-year and 3-years after HCT
was significantly decreased for recipients with LONIPC compared
to those without LONIPC (1 year OS 51% vs. 76%, p\0.01) and
(3 yearsOS 34% vs 57%, p\0.01). 45%of recipients with LONIPC
survived 6 months after developing lung complication. Among pa-
tients with LONIPC, those with DAH and IPS had worse survival
at 1-year after HCT compared to patients with BO (36% vs. 37%
vs. 77%, p\0.01). LONIPC in allogeneic HCT recipients consists
of a heterogeneous group of diseases with varying clinical course and
prognosis. LONIPC is associated with increased mortality among
HCT receipients.Further understanding of the pathogenesis of
each of these entities is still required.184
NEPHROTIC SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC CELL
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The NIH Consensus recognizes nephrotic syndrome (NS) as part
of the chronic GVHD symptomatology, however the incidence and
outcomes of this manifestation have not been well-defined. To char-
acterize this complication, we conducted an IRB-approved retro-
spective review of 626 consecutive patients (age. 16 yrs: [MRD],
n5 352; [MUD], n5 274) who underwent allogeneic hematopoietic
cell transplantation (HCT) between October 2000 and December
2007 at theUniversity ofMichigan. Conditioning regimens included
full intensity (FIC) in 470 patients and reduced intensity (RIC) in 156
patients. Nephrotic range proteinuria was identified in 17 patients.
Renal biopsy confirmed the diagnosis in seven of these patients.
The median time to onset of NS was 7.3 months following HCT.
Clinical manifestations included hypoalbuminemia (100%), hyper-
cholesterolemia (82%), edema (76%), renal impairment (65%),
and thrombosis (29%). The overall cumulative incidence of NS
was 2.9%: 2.4% in FIC and 4.6% in RIC HCT recipients; and
2.3% inMRD and 3.7%MUDHCT recipients. Of note, in patients
who received irradiation-based conditioning regimens, there was an
increased cumulative incidence of NS compared to those who did
not, 4.8% versus 2.1%, respectively.
Diagnostic symptoms of chronic GVHD based upon the NIH
Consensus was seen in 11 patients (65%). Prior history of acute
GVHD was seen in 11 patients (65%). Interestingly, history of
symptomatic cystitis was seen in 9 patients (53%), eight of whom
had BK virus detected in the urine. All of the patients received sys-
temic steroids (0.25 mg/kg – 2 mg/kg), with or without mycopheno-late mofetil and a calcineurin inhibitor. Additional therapy with
rituximab was administered in nine patients. Durable remission
with no further recurrence of proteinuria was observed in 47% of
the patients (n5 8). The median time to response was 4.8 months.
Recurrence of proteinuria was seen in 29% of the patients (n5 5),
and primary refractory proteinuria was observed in 23% of the pa-
tients (n5 4). Overall survival for the cohort was 49.5% at 4 years
with median follow up of 5.1 years. The median survival from diag-
nosis ofNSwas 2.5 years. As ofMay 2009, eight patients are alive and
nine have died. The causes of death include GVHD (n5 6), relapse
(n5 2) and unknown (n5 1). NS is a rare but important complica-
tion following allogeneicHCT. Early recognition of the clinical pre-
sentations and risk factors may limit the potential morbidity and
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UTILIZATION OF PREVENTIVE CARE SERVICES BY HEMATOPOIETIC CELL
TRANSPLANT SURVIVORS
Lee, S.J., Leisenring, W.M., Khera, N., Chow, E.J., Syrjala, K.L.,
Baker, K.S., Flowers, M.E.D., Martin, P.J. Fred Hutchinson Cancer Re-
search Center, Seattle, WA
Background andMethods: Screening and preventive care guidelines
are available for survivors of autologous and allogeneic hematopoietic
cell transplantation (HCT).We assessed adherence to these guidelines
with a mailed questionnaire sent to all adult survivors in the Fred
Hutchinson Cancer Research Center database, and examined factors
associated with adherence.
Results:Of 3780 survivors after HCT, 1849 (49%) responded. Me-
dian age of respondents at the time of the survey was 55.3 years (18.2-
81.2). 53% were male, 90% White, 68% allogeneic recipients, and
the median time elapsed since transplant was 8.1 years (0.2-38.1).
Younger age, male gender, non-White race, bone marrow trans-
plant, myeloablative conditioning, allogeneic HCT, and HCT in
